Telix to Acquire ITM in $1.65 Billion Radiopharmaceutical Merger, Adding Late-Stage GEP-NET Therapy ITM-11
核心洞察
Telix Pharmaceuticals has signed a strategic agreement to acquire 100% of privately held ITM Isotope Technologies Munich for US$1.65 billion upfront on a cash-free, debt-free basis.
The deal adds up to US$700 million in contingent consideration tied to FDA approvals and sales milestones for ITM-11, a 177Lu-edotreotide therapy for gastroenteropancreatic neuroendocrine tumors (搜索).
ITM is the only producer of globally scaled commercial-grade lutetium-177 and supplies radioisotopes across a distribution network spanning more than 65 countries.
Telix Pharmaceuticals Limited has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (搜索), acquiring 100% of the privately held German radiopharmaceutical company for US$1.65 billion upfront on a cash-free, debt-free basis. The transaction, announced Sept. 21, 2026, combines Telix's commercial-stage theranostics platform with ITM's commercial-scale radioisotope manufacturing and global distribution network.
The merger is structured to deepen Telix's isotope supply chain while adding a late-stage therapeutic asset in a validated commercial market for targeted radionuclide therapy (TRT). ITM's pipeline includes ITM-11 (177Lu-edotreotide), a somatostatin receptor (搜索) (SSTR)-targeted candidate for gastroenteropancreatic neuroendocrine tumors (搜索) (GEP-NETs) that has completed a successful Phase 3 trial (COMPETE, NCT03049189) and fully enrolled a second indication-expansion Phase 3 study (COMPOSE, NCT04919226), with an interim analysis expected in the first half of 2027.
Isotope Manufacturing at Commercial Scale
Founded in 2004, ITM operates two GMP manufacturing sites in Munich and a global distribution network spanning more than 65 countries. The company is the only producer of globally scaled commercial-grade lutetium-177 (177Lu) and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals. Its capabilities span 177Lu, actinium-225 (225Ac) and terbium-161 (161Tb) production.
ITM reported annual revenue of US$273 million in 2025, reflecting a compound annual growth rate of 40% from 2021 to 2025. The company's isotope production business is profitable and generates cash flow. Through an agreement with Isogen, ITM holds 15-year exclusive access to Bruce Power's nuclear reactors in Canada for the irradiation services required to manufacture 177Lu.
The global nuclear medicine market is forecast to reach US$41 billion by 2034, according to the announcement.
Deal Terms and Milestone Structure
Under the agreement, US$1.25 billion will be paid to ITM sellers in the form of 105.8 million Telix shares, priced at a 30-day trailing VWAP of US$11.84 as of signing, released as Nasdaq-listed ADRs after respective escrow periods. Telix will assume US$302 million of net debt at closing, and US$96 million of management equity rollover and transaction expenses are payable by the sellers, in each case subject to closing adjustments.
An additional US$700 million in contingent consideration is tied to ITM-11 milestones. Up to US$250 million is payable upon FDA approval across three indications: US$100 million for the expected first indication in G1-G2 GEP-NETs no later than Dec. 31, 2027; US$100 million for a G2-G3 GEP-NETs indication no later than Dec. 31, 2030; and US$50 million for a lung NETs indication no later than Dec. 31, 2031. A further US$450 million is payable based on ITM-11 net global sales in FY 2030 exceeding US$150 million. All milestone consideration is payable in cash or shares at Telix's election.
Upon completion, Telix shareholders will own approximately 76.3% and ITM shareholders approximately 23.7% of Telix shares on issue. The transaction has been approved by Telix's Board of Directors and, as of signing, by shareholders holding over 90% of ITM's shares. Closing is expected by the end of FY 2026, subject to Telix shareholder approval under ASX Listing Rules, regulatory approvals and other customary conditions. A notice of meeting will be sent to Telix shareholders for an extraordinary general meeting expected in November 2026.
Combined Pipeline and Financial Profile
The combined organization is expected to generate unaudited pro forma 2026 revenue and income exceeding US$1.3 billion, based on management estimates. Continued growth from manufacturing, cost savings and further targeted synergies and pipeline optimization are expected to support a positive EBITDA contribution in 2027 and onward.
Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S.; Gozellix (搜索) (kit for the preparation of gallium-68 gozetotide injection), approved by the FDA for prostate imaging; and Pixclara (floretyrosine F 18), approved by the FDA for glioma imaging. Its late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (搜索) (lutetium-177 rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (搜索) (iodofalan 131I) in recurrent glioblastoma, and TLX250-Tx (搜索) (lutetium-177 girentuximab tetraxetan) in kidney cancer. None of these three candidates has received marketing authorization in any jurisdiction.
Telix Managing Director and Group CEO Dr. Christian Behrenbruch said the merger positions Telix at the forefront of industry consolidation. "ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation," he said. "By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector."
ITM Chief Executive Officer Dr. Andrew Cavey said the combination creates a company with breadth and depth across the value chain. "Together, we believe Telix and ITM will be uniquely positioned to capitalize on rapidly growing global demand for radiopharmaceuticals to the benefit of both shareholders and patients," he said.
The radiopharmaceutical field is currently dominated by Novartis, which launched two such treatments in 2018 and 2022. These medicines work by delivering radioactive isotopes directly to cancer cells.